Emerging preclinical autism research has shown the therapeutic promise of pharmacological inhibitors for epigenetic enzymes, such as histone deacetylases (HDAC), euchromatic histone methyltransferases (EHMT), and lysine-specific histone demethylase 1A (LSD1). These interventions restore gene expression, synaptic function, and behavioral performance in autism models, highlighting a new strategy for autism treatment.

中文翻译：

---

针对自闭症治疗的表观遗传酶

新兴的临床前自闭症研究表明表观遗传酶的药物抑制剂具有治疗前景，例如组蛋白脱乙酰酶 (HDAC)、常染色质组蛋白甲基转移酶 (EHMT) 和赖氨酸特异性组蛋白脱甲基酶 1A (LSD1)。这些干预措施恢复了自闭症模型中的基因表达、突触功能和行为表现，凸显了自闭症治疗的新策略。